DELIX THERAPEUTICS

delix-therapeutics-logo

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale.

#SimilarOrganizations #People #Financial #Event #Website #More

DELIX THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Life Science

Founded:
2019-01-01

Address:
Boston, Massachusetts, United States

Country:
United States

Website Url:
http://www.delixtherapeutics.com

Total Employee:
1+

Status:
Active

Total Funding:
118 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Microsoft Exchange Online Amazon Office 365 Mail


Similar Organizations

aracari-biosciences-logo

Aracari Biosciences

Aracari is a Drug discovery company.

lunac-therapeutics-logo

Lunac Therapeutics

Lunac Therapeutics is a UK-based drug discovery company.


Current Advisors List

vasudev-bailey_image

Vasudev Bailey Board Member @ Delix Therapeutics
Board_member

Current Employees Featured

brigitte-robertson_image

Brigitte Robertson
Brigitte Robertson Chief Medical Officer @ Delix Therapeutics
Chief Medical Officer
2021-08-01

retsina-meyer_image

Retsina Meyer
Retsina Meyer Head of Strategic Projects and Alliances @ Delix Therapeutics
Head of Strategic Projects and Alliances
2021-03-01

mark-rus_image

Mark Rus
Mark Rus Chief Executive Officer @ Delix Therapeutics
Chief Executive Officer
2021-03-01

not_available_image

David E. Olson
David E. Olson CO-founder, president @ Delix Therapeutics
CO-founder, president
2021-07-01

nick-haft_image

Nick Haft
Nick Haft Co-Founder @ Delix Therapeutics
Co-Founder
2019-07-01

Founder


not_available_image

David E. Olson

nick-haft_image

Nick Haft

Investors List

comerica-technology-life-sciences_image

Comerica - Technology & Life Sciences

Comerica - Technology & Life Sciences investment in Debt Financing - Delix Therapeutics

wpss-investments_image

WPSS Investments

WPSS Investments investment in Series A - Delix Therapeutics

bail-capital_image

Bail Capital

Bail Capital investment in Series A - Delix Therapeutics

vertical-venture-partners_image

Vertical Venture Partners

Vertical Venture Partners investment in Series A - Delix Therapeutics

negev-capital_image

Negev Capital

Negev Capital investment in Series A - Delix Therapeutics

casa-verde-capital_image

Casa Verde Capital

Casa Verde Capital investment in Series A - Delix Therapeutics

omx-ventures_image

OMX Ventures

OMX Ventures investment in Series A - Delix Therapeutics

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series A - Delix Therapeutics

apeiron-holdings-limited-2_image

Apeiron Holdings Limited

Apeiron Holdings Limited investment in Series A - Delix Therapeutics

ocama-partners_image

Ocama Partners

Ocama Partners investment in Series A - Delix Therapeutics

Official Site Inspections

http://www.delixtherapeutics.com Semrush global rank: 3.92 M Semrush visits lastest month: 3.22 K

  • Host name: ec2-54-237-159-171.compute-1.amazonaws.com
  • IP address: 54.237.159.171
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Delixtherapeutics.com lookup results from whois.srsplus.com server:
  • Domain created: 19th-Feb-2019
  • Domain updated: 6th-Jun-2023
  • Domain expires: 19th-Feb-2025 0 Years, 38 Days left
  • Website age: 5 Years, 327 Days
  • Registrar Domain ID: 2362071409_DOMAIN_COM-VRSN
  • Registrar Url: http://www.srsplus.com
  • Registrar WHOIS Server: whois.srsplus.com
  • Registrar Abuse Contact Email: domain.operations@web.com
  • Registrar Abuse Contact Phone: +1.8777228662
  • Name server:
    • NS11.CONSTELLIX.COM
    • NS21.CONSTELLIX.COM
    • NS31.CONSTELLIX.COM
    • NS41.CONSTELLIX.NET
    • NS51.CONSTELLIX.NET
    • NS61.CONSTELLIX.NET

More informations about "Delix Therapeutics"

Delix Therapeutics - Wikipedia

In 2021, Delix was named one of the Fierce 15 of Biotech. In 2022, Nature named Delix Spinout of the Year and Delix was awarded the Healthcare Businesswomen's Association (HBA) ACE award. In 2023, Delix was a finalist for the Prix Galien award for Best Startup and the BWB award for Biotech Innovation of the Year and won the Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year. See details»

Delix Therapeutics - Crunchbase Company Profile

Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.See details»

Delix Company Profile 2024: Valuation, Funding & Investors

Information on valuation, funding, cap tables, investors, and executives for Delix. Use the …See details»

Our Team Pushing the Boundaries of Neuroscience - Delix …

Meet the team of Delix innovators pushing the frontiers of neuroscience and developing novel …See details»

Delix Therapeutics - LinkedIn

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class ...See details»

For Investors - Delix Therapeutics

Join world class investors partnered with Delix to support pursuing advanced neurological treatments leveraging rapid, sustained & scalable neuroplastogensSee details»

UC Davis-Enabled Startup Delix Therapeutics Secures …

By Neelanjana Gautam October 8, 2021 UC Davis-enabled neuroscience startup Delix Therapeutics recently closed a $70 million Series A funding round. Co-founded by David E. Olson, associate professor in the Department of …See details»

Delix Therapeutics Awarded National Institutes of Health Grant to ...

BEDFORD, Mass., December 13, 2023--Delix Therapeutics Awarded National Institutes of …See details»

Delix

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics.See details»

Delix raises $70 million to synthesize psychedelic-inspired drugs

Sep 27, 2021 In 2019, Olson cofounded Delix to recruit a team of chemists up to the task. …See details»

Delix Therapeutics Expands Executive Leadership Team - PR …

BOSTON, July 6, 2021 /PRNewswire/ -- Preclinical neuroscience company Delix Therapeutics …See details»

Pioneering Next-Gen Neuroplasticity Therapies - Delix Therapeutics

At Delix, our singular focus is pushing the boundaries of neuroscience to treat conditions of the …See details»

Delix Announces DLX-001 Demonstrates Evidence of CNS …

BEDFORD, Mass., May 13, 2024--Delix Therapeutics, a clinical-stage neuroscience company …See details»

Nature Biotechnology Selects Delix Therapeutics as a Leading …

Fast growing neuroscience company featured by Nature as a top academic spinout, …See details»

Delix Therapeutics Closes $70 Million Series A Financing to …

BOSTON, Sept. 27, 2021 /PRNewswire/ -- Preclinical neuroscience company Delix …See details»

Delix Announces DLX-001 Demonstrates Evidence of CNS …

May 13, 2024 Investor Relations: Retsina Meyer, PhD Delix Therapeutics …See details»

Delix Therapeutics Co-Founder Publishes Groundbreaking Study ...

BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company …See details»

Delix in the News - Delix Therapeutics

Find the latest news articles, media, and press releases about Delix Therapeutics’ scientific, …See details»

Delix Pipeline of Psychoplastogens and Neuroplastogens - Delix …

Our diversified pipeline lauds more than 1500 compounds based on more than 10 unique …See details»

linkstock.net © 2022. All rights reserved